| abstract |
The invention relates to new substituted heteroaryls of the formula 1 or the formula 1 ': in which A is either N or CH; R is selected from the group consisting of —Calkyl, —Caloalkyl, F, Br, Cl; Y is selected from —O— or —CH— and R is defined as in claim 1, and their pharmaceutically acceptable salts, as well as the use of the above compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis , erythematous lupus, lupus nephritis, and rheumatoid arthritis. |